Chemed Corporation (NYSE: CHE) reported Q1 EPS of $1.82, $0.03 better than the analyst estimate of $1.79. Revenue for the quarter came in at $406 million versus the consensus estimate of $399.76 million.

Guidance:

"Revenue growth for VITAS in 2017, prior to Medicare Cap, is estimated to be in the range of 4% to 5%. Admissions and Average Daily Census in 2017 are estimated to expand approximately 3% to 4% and full-year Adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 14.5% to 15.0%. We are currently estimating $3.7 million for Medicare Cap billing limitations in the 2017 calendar year."

For earnings history and earnings-related data on Chemed Corporation (CHE) click here.